Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer (VESTOR)

Phase II Trial, Evaluating Efficacy of Temsirolimus (Torisel ®) in Second Line Therapy for Patients With Advanced Bladder Cancer

In the absence of standard treatment in this indication, this test evaluates a new drug type targeted therapy in this indication, evaluating its efficacy in terms of tumor response and survival.

Study Overview

• Status: Completed
• Conditions: Relapsed Bladder Cancer
• Intervention / Treatment: Drug: Temsirolimus

Detailed Description

In the absence of standard treatment in this indication, this test evaluates a new drug type targeted therapy in this indication, evaluating its efficacy in terms of tumor response and survival. This study will also search for genes involved in the response to treatment.

• Study Type: Interventional
• Enrollment (Actual): 54
• Phase: Phase 2

Contacts and Locations

Study Locations

• France
  • Bordeaux, France, 33076
    • CHU de Bordeaux
  • Caen, France, 14076
    • Centre François Baclesse
  • Clermont Ferrand, France, 63011
    • Centre Jean Perrin
  • Créteil, France, 94010
    • CHU Henri Mondor
  • Lyon, France, 69373
    • Centre Leon Bérard
  • Paris, France, 75230
    • Hôpital d'instruction des armées du Val-de-Grâce
  • Rouen, France, 76031
    • CHU de Rouen
  • Toulouse, France, 31052
    • Institut Claudius Regaud
  • Toulouse, France, 31059
    • CHU de Toulouse

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Men or women of at least 18 years of age
• Histologically proven Bladder cancer
• Locally advanced or metastatic disease (stage IV)
• Functional status (ECOG / OMS) ≤ 2
• Relapse after first-line chemotherapy
• Measurable lesions (RECIST criteria)
• Absence of anti-neoplasic treatment in the 4 weeks preceding inclusion.
• Biological levels :
• Neutrophil count >1,5.109/L.
• Platelets >100.109/L
• Total serum bilirubin < 1.5 × ULN
• Clearance of créatinine 40 ml/mm
• If not liver metastasis alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2.5 × ULN
• With liver alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <5 × ULN
• Signed informed consent
• Both women and men must agree to use a medically acceptable method of contraception throughout the study. Women of childbearing potential must have a negative serum pregnancy test of or less than 7 days before the first perfusion of study.
• France only : Patients affiliated to a social security program

Exclusion Criteria:

• Presence of metastatic brain or meningeal tumors on selection scanner, weither symptomatic or asymptomatic
• Chemotherapy, immunotherapy, or radiotherapy within 4 weeks of inclusion
• Known hypersensitivity to temsirolimus, or its metabolites (as sirolimus), or polysorbate 80 or to their excipients
• Previous malignancy (except for cervical carcinoma in situ, basal cell carcinoma curatively treated) or incidental (≤ pT2) prostate cancer found on a radical cystoprostatectomy material
• The drugs known as CYP3A4/5 inhibitors or inducers will specifically be excluded on the 30th day ( or at least 7 halves-lives, according to the shortest duration) before the first perfusion and throughout the study. Any food known to inhibit CYP3A4/5 (for example grapefruit, grapefruit juice, star-fruit or star-fruit juice) will also be purposely excluded.
• Auto-immune pathology, psychiatric or neurological disorder
• Any unstable medical condition
• Unstable cardiac disease
• Severe renal failure
• Unstable diabetes
• Pregnancy
• Patient enrolled in another therapeutic clinical trial
• Patient unable to follow and comply with the study procedures because of any geographical, social or medical condition
• Patient partially or totally deprived of his civil rights

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Temsirolimus; Temsirolimus was administered intravenously at a dose of 25 mg in a weekly 30 min infusion and was associated to anti-H1 treatment. One cycle corresponded to 4 weeks of treatment.	Drug: Temsirolimus; Temsirolimus; Other Names: Torisel

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Non-progression Rate at 2 Months	Non-progression rate is defined as the rate of participants in complete or partial response or stable disease according to RECIST V1.1. Complete response is defined as the disappearance of all target lesions, partial response is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters and stable disease occurs when neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progression, taking as reference the smallest sum diameters while on study.	2 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival	OS was was defined as the time from the treatment initiation to death due to any cause. Participants without documented death were censored at the date of the last follow-up or last patient contact. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data.	Through Database Cutoff Date of 23-Jan-2015 (up to approximately 5 years and 7 months - median follow-up time of 14 months)
Progression-free Survival	Progression-free survival (PFS) was defined as the time from the initiation of treatment to the first documented progression (as per RECIST v1.1) or death (due to any cause), whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Patients alive and progression free were censored at the date of last follow-up or last patient contact. The PFS per RECIST 1.1 was calculated using the product-limit (Kaplan-Meier) method for censored data.	Through Database Cutoff Date of 23-Jan-2015 (up to approximately 5 years and 7 months - median follow-up time of 14 months)

Collaborators and Investigators

• Sponsor: Institut Bergonié
• Collaborators: Wyeth is now a wholly owned subsidiary of Pfizer
• Investigators: Study Chair: Nadine HOUEDE, MD, Institut Bergonié

Publications and helpful links

General Publications

• Pulido M, Roubaud G, Cazeau AL, Mahammedi H, Vedrine L, Joly F, Mourey L, Pfister C, Goberna A, Lortal B, Bellera C, Pourquier P, Houede N. Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer. BMC Cancer. 2018 Feb 17;18(1):194. doi: 10.1186/s12885-018-4059-5.

Study record dates

Study Major Dates

• Study Start: June 1, 2009
• Primary Completion (Actual): December 1, 2014
• Study Completion (Actual): December 1, 2016

Study Registration Dates

• First Submitted: October 29, 2012
• First Submitted That Met QC Criteria: April 9, 2013
• First Posted (Estimate): April 10, 2013

Study Record Updates

• Last Update Posted (Actual): May 6, 2021
• Last Update Submitted That Met QC Criteria: April 9, 2021
• Last Verified: April 1, 2021

More Information

Terms related to this study

• Keywords: Relapsed bladder cancer
• Additional Relevant MeSH Terms: Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Urologic Diseases; Urinary Bladder Diseases; Urinary Bladder Neoplasms; Physiological Effects of Drugs; Anti-Infective Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antifungal Agents; Sirolimus
• Other Study ID Numbers: IB2009-08